Wall Street analysts forecast that Agenus Inc (NASDAQ:AGEN) will report $5.37 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Agenus’ earnings, with the highest sales estimate coming in at $9.30 million and the lowest estimate coming in at $1.43 million. The business is expected to issue its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that Agenus will report full year sales of $69.53 million for the current fiscal year, with estimates ranging from $16.50 million to $107.90 million. For the next year, analysts forecast that the business will post sales of $15.42 million, with estimates ranging from $2.76 million to $27.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, May 9th. The biotechnology company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.42. The business had revenue of $8.61 million for the quarter, compared to analyst estimates of $9.03 million.
A number of analysts have recently weighed in on AGEN shares. B. Riley set a $33.00 target price on Triumph Bancorp and gave the company a “buy” rating in a research report on Monday, April 22nd. BidaskClub cut Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday.
AGEN remained flat at $$2.53 during trading on Friday. The company had a trading volume of 906,761 shares, compared to its average volume of 1,320,901. The firm’s 50 day moving average price is $2.76. The stock has a market capitalization of $331.62 million, a P/E ratio of -1.76 and a beta of 1.86. Agenus has a twelve month low of $1.54 and a twelve month high of $3.88.
A number of large investors have recently made changes to their positions in the business. Shell Asset Management Co. bought a new position in shares of Agenus in the first quarter valued at approximately $197,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Agenus in the fourth quarter valued at $80,000. Bank of New York Mellon Corp grew its position in shares of Agenus by 26.6% in the fourth quarter. Bank of New York Mellon Corp now owns 442,886 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 92,957 shares in the last quarter. Millennium Management LLC boosted its stake in Agenus by 58.8% during the fourth quarter. Millennium Management LLC now owns 1,021,387 shares of the biotechnology company’s stock valued at $2,431,000 after buying an additional 378,345 shares during the period. Finally, RTW Investments LP boosted its stake in Agenus by 3.2% during the fourth quarter. RTW Investments LP now owns 10,135,119 shares of the biotechnology company’s stock valued at $24,122,000 after buying an additional 310,540 shares during the period. Institutional investors and hedge funds own 33.08% of the company’s stock.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More: What is a support level?
Get a free copy of the Zacks research report on Agenus (AGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.